Background. Individual-level simulation models are valuable tools for comparing the impact of clinical or public health interventions on population health and cost outcomes over time. However, a key challenge is ensuring that outcome estimates correctly reflect real-world impacts. Calibration to targets obtained from randomized trials may be insufficient if trials do not exist for populations, time periods, or interventions of interest. Observational data can provide a wider range of calibration targets but requires methods to adjust for treatment-confounder feedback. We propose the use of the parametric g-formula to estimate calibration targets and present a case-study to demonstrate its application. Methods. We used the parametric g-formula applied to data from the HIV-CAUSAL Collaboration to estimate calibration targets for 7-y risks of AIDS and/or death (AIDS/death), as defined by the Center for Disease Control and Prevention under 3 treatment initiation strategies. We compared these targets to projections from the Cost-effectiveness of Preventing AIDS Complications (CEPAC) model for treatment-naı¨ve individuals presenting to care in the following year ranges: 1996 to 1999, 2000 to 2002, or 2003 onwards. Results. The parametric gformula estimated a decreased risk of AIDS/death over time and with earlier treatment. The uncalibrated CEPAC model successfully reproduced targets obtained via the g-formula for baseline 1996 to 1999, but over-estimated calibration targets in contemporary populations and failed to reproduce time trends in AIDS/death risk. Calibration to g-formula targets improved CEPAC model fit for contemporary populations. Conclusion. Individual-level simulation models are developed based on best available information about disease processes in one or more populations of interest, but these processes can change over time or between populations. The parametric g-formula provides a method for using observational data to obtain valid calibration targets and enables updating of simulation model inputs when randomized trials are not available.
Simulation models, such as agent-based, microsimulation, or individual-level models, are often used to estimate the population impact of implementing public health interventions or clinical treatment strategies. Individual-level simulation models estimate (counterfactual) outcome distributions under alternative policy or treatment strategies, and therefore answer causal questions of the form: What would the outcome distribution in a population be if a particular strategy had been implemented?
An individual-level simulation model is defined by parameters that describe the relationships among treatments, outcomes, and other variables. 1 A key practical challenge to creating these models is that these parameters cannot be directly estimated from the population of interest. Otherwise, the outcome distributions could be estimated directly from the data using causal inference techniques rather than via simulation. Instead, model parameters typically need to be selected from a variety of sources and thus calibration procedures are required before the model can be applied to the population of interest. [2] [3] [4] [5] Calibration is the process of comparing the simulation model results to outcome distributions estimated using another analytic method, and has 2 steps. First, investigators must identify appropriate benchmarks as calibration targets. Second, they must ensure that the simulation model reproduces these targets in the population of interest. 4 A large literature is devoted to the second step, including methods for searching the input parameter space and determining goodness of fit. [6] [7] [8] [9] Here, we focus on the first step, for which 2 broad types of calibration targets may be of interest.
One possible target is the observed outcome distribution in the population of interest. This can be estimated via a randomized trial or using observational data. 5 However, replicating the observed outcomes requires knowing the distribution of treatment strategies in the population so that these can be included in the analysis. This information may be difficult to obtain except from randomized trials, where it is fixed by design. Because of this, randomized trials are often seen as the goldstandard for obtaining calibration targets but there are several limitations to relying solely on randomized trials. First, a given trial typically compares only a limited number of interventions, and the particular strategies of interest for a model may not be included. Second, trials are often not available in the population for which the simulation model is being calibrated, or may have been conducted in a highly specific subset of the population and thus of limited generalizability.
A second possible target is the counterfactual outcome distribution under a single treatment strategy selected from among the strategies present in the population. If sufficient observational data are available from the population of interest, this distribution can be validly estimated using causal inference techniques, such as the parametric g-formula, which is a generalization of standardization to settings with time-varying treatment and confounders 10, 11 and similar in many aspects to individual-level simulation models. 12 Here, we propose the application of the parametric gformula to obtain a range of calibration targets for individual-level simulation models when longitudinal data (on treatments, outcomes, and confounders) is available in a population of interest. As a case study, we apply the parametric g-formula to observational data to estimate calibration targets for the Cost-effectiveness of Preventing AIDS Complications (CEPAC) model. We consider the question of when to initiate antiretroviral therapy (ART) for people living with HIV.
The structure of this paper is as follows. We first describe the scenario of interest, the observational dataset, and the parametric g-formula. We then describe the estimation of calibration targets, the CEPAC model, and the calibration process. The calibration process is presented in 2 stages: 1) estimation of the calibration targets via the parametric g-formula and assessment of original parameterization fit, and 2) update of model parameters to improve fit. We conclude with a discussion of the assumptions required for the parametric g-formula to validly estimate the true counterfactual outcome distributions.
Methods

Scenario
We consider 3 treatment initiation strategies for people living with HIV in Europe and North America: 1) immediate ART initiation at diagnosis of HIV infection (currently recommended in the US); 2) early ART initiation when CD4 count falls below 500 cells/ml; and 3) late ART initiation when CD4 count falls below 350 cells/ml. ART is defined as a regimen of antiretroviral drugs including at least 2 nucleoside reverse transcriptase inhibitors (NRTIs) and either one or more protease inhibitors (PI) or boosted PIs, one non-nucleoside reverse transcriptase inhibitor (NNRTI), one integrase inhibitor (INSTI), one entry or fusion inhibitor, or 3 or more NRTIs.
Until relatively recently, it was debated whether the benefits of early treatment initiation might be offset by an increased risk of side effects and resistance that limits future treatment options. [13] [14] [15] As of 2017, these strategies have been assessed in both observational cohorts and randomized trials, and there is consensus that early initiation is preferable. We use these strategies here as simple demonstration targets [16] [17] [18] but the same approach described here could be applied to a wider range of strategies or to more complex strategies, such as scheduled treatment interruption plans or treatment switching strategies, provided data exist.
We considered 2 types of outcomes: death and a combined outcome of death or AIDS (defined as first diagnosis of an AIDS-defining opportunistic illness 19 ). For each outcome, we estimated 2 calibration targets: the 7-y outcome risk and the 7-y survival curve under each treatment initiation strategy.
Data Source
We used data from the HIV-CAUSAL Collaboration 20, 21 to estimate our calibration targets. This collaboration combines data from prospective cohorts of HIV-positive individuals in Brazil, Canada, France, Greece, Netherlands, Spain, Switzerland, UK, and USA. We excluded data from Brazil from our analyses because a separate parameterization of the CEPAC model exists for Brazil. The estimates presented here are based on data pooled in December 2015.
Our analyses included all HIV-positive individuals in the HIV-CAUSAL Collaboration aged 18 years or older, who were ART-naı¨ve, did not have AIDS, were not pregnant, and had a CD4 cell count and HIV RNA measurement within the past 3 mo of baseline. The start of follow-up for each individual was defined as the first month in which all eligibility criteria were met during 3 baseline time periods: 1996-1999, 2000-2002, and 2003 onwards.
Each individual was followed until death; censoring, defined as 12 mo after the last recorded CD4 cell count and HIV RNA measurements or pregnancy (if known); or the study-specific administrative end of follow-up between February 2010 and March 2013. Unlike in a previous application of the parametric g-formula to estimate the impact of treatment initiation on survival in these data, 17 we did not require that baseline occur within 6 mo of HIV diagnosis because the date of diagnosis is not used in CEPAC.
Parametric g-Formula
We used the parametric g-formula to estimate our calibration targets adjusting for time-fixed and time-varying confounders. 10, 11, 22 The implementation of the parametric g-formula involves 2 steps: 1) parametric estimation of the joint distribution of covariates and outcome over time; 2) simulation of the counterfactual outcome distribution under different treatment strategies. 22 A brief description of each step follows. For more details, we refer readers to previous applications of the parametric g-formula. 17, [22] [23] [24] Step I: Parametric Estimation of the Joint Distribution of the Data. As in previous analyses, [16] [17] [18] we considered the following covariates: baseline CD4 count in cells/ml (\50, 50-99, 100-199, 200-349, 350-499, 500), HIV RNA log copies per mL (\4, 4-5, .5), sex, race, geographical origin (Europe and the USA, sub-Saharan Africa, rest of the world, unknown), transmission group (heterosexual, homosexual or bisexual, injection drug user, and other/unknown), age in years (\35, 35-50, .50), calendar year (\2000, 2000-2004, 2005-2010, 2011-2013) , and cohort; and time-varying CD4 cell count, HIV RNA, and AIDS (when not an outcome). Importantly, these time-varying confounders are also affected by prior treatment history leading to treatmentconfounder feedback.
We next fit parametric regression models to the HIV-CAUSAL data to estimate the joint distribution of the time-varying covariates, treatment initiation, and mortality over time. We used logistic regression to model the time-varying indicators for death, AIDS, and treatment initiation, and linear regression to model the natural logarithms of HIV RNA and CD4 cell count. All models included the 2 most recent values of the time-varying covariates, as well as time since last CD4 count and HIV RNA measurements, and all baseline covariates. Models for CD4 count and HIV RNA also included product terms for the number of months since ART initiation.
Step II: Estimation of the Counterfactual Outcome Distribution under Several Treatment Strategies. For each treatment strategy, we used the parametric models fit in Step I to generate a cohort of the same size as the original data via Monte-Carlo simulation. At each time point, we assigned treatment according to the treatment strategy. We then calculated the outcome distribution in the simulated data.
We used non-parametric bootstraps with 500 samples to obtain 95% confidence intervals. For each bootstrap, we took a random sample of the HIV-CAUSAL data with replacement and repeated the full process of Steps I to II. We then calculated the 95% confidence intervals based on the 2.5 th and 97.5 th percentiles of the bootstrap outcome estimates. All analyses were conducted using the GFORMULA macro 25 in SAS 9.4. As a sensitivity analysis, we estimated the outcome distributions under no intervention. That is, we assigned treatment at each month based on the estimated conditional probability of treatment observed in the HIV-CAUSAL data from Step II.
CEPAC Model
We calibrated the CEPAC model, a large, wellestablished, individual-level simulation model that can assess the cost-effectiveness of a range of clinical and public health policies aimed at reducing the burden of disease and improving survival among people living with HIV. [26] [27] [28] Simulated individuals in CEPAC exist in 1 of 3 health states: chronic infection, acute opportunistic infections (OIs), or death. Time-varying covariates, including CD4 count, HIV RNA level, age, and sex, govern transitions between health states. There are 3 distinct probabilities that govern mortality each month: the probability of chronic AIDS-related mortality, the probability of acute OI-related mortality, and the probability of non-AIDS-related mortality. Full specification of the model is provided on the CEPAC website 29 and elsewhere. 27, 30 The CEPAC model was originally designed using data from the Multicenter AIDS Cohort Study (MACS)-a cohort study of HIV-positive men which began enrollment in 1984. 31 CEPAC was originally calibrated to data from cohorts of people living with HIV in the US; the prior calibration is described in detail elsewhere. 32 However, changes in available treatments, testing strategies, and demographics of people living with HIV over time required that the model be periodically recalibrated to ensure it continues to provide valid estimates of survival and AIDS progression in contemporary settings. Here, we compared the estimated outcome distributions from CEPAC to calibration targets obtained using the parametric g-formula applied to HIV-CAUSAL data in the 3 baseline time periods. Because more recent cohort data more accurately reflect the current clinical course of HIV disease and treatment, we aimed for the recalibrated model to better fit the data from 2003 onwards.
Calibration
We simulated each treatment strategy and time period in CEPAC using 100,000 individuals. For each simulated population, we used the observed baseline distributions of CD4 count (mean and standard deviation), HIV RNA strata (% within strata), age (mean and standard deviation), gender (% male), and transmission risk group from individuals in HIV-CAUSAL who met the inclusion criteria within that baseline time period (Table 1 , Appendix 1).
We used a previously published set of CEPAC parameter values for modeling AIDS-related mortality, OI incidence, and changes to CD4 count and HIV RNA over time (Table 2) . 27, 31, [33] [34] [35] Sex-stratified lifetables for the probability of non-AIDS-related mortality were obtained from the Eurostat website. 36 Key parameter values are given in Table 2 . For more detail on these parameters, their sources, and how they govern transitions between health states in CEPAC see Appendix 2.
We focused our calibration on 2 parameters, selected because their initial values had been determined based on discussions with clinicians and other experts in the field, without a substantial empirical evidence base. Specifically, we assessed the on-treatment multiplier for OI incidence and the on-treatment multiplier for chronic AIDS-related mortality. In the original CEPAC calibration, both multipliers were set to 1.0. We performed a grid search by varying the on-treatment multipliers jointly between 1 and 0 by 0.2 units for a total of 36 calibration runs. We chose a simple grid search, rather than a more formal search procedure, such as Nelder Mead, because our goal was chiefly to demonstrate the method of obtaining calibration targets rather than performing a full calibration of CEPAC.
We assessed the fit of the 7-y mortality and combined AIDS or mortality risks from the calibration runs in comparison to the values of the calibration targets estimated using the parametric g-formula applied to HIV-CAUSAL. Fit was determined based on the number of treatment strategies and outcomes for which the CEPAC risk estimates were within the 95% confidence intervals for the g-formula risk estimates. We also visually inspected survival and AIDS-free survival curves produced by the calibration runs of CEPAC and those obtained via the g-formula.
As sensitivity analyses, we compared the distributions of mean CD4 count and HIV RNA over time estimated using CEPAC and the parametric g-formula (Appendix 3), and assessed the impact on the CEPAC model results of varying a range of additional input parameters (Appendix 4). Table 3 compares the observed risks from HIV-CAUSAL with those estimated via the g-formula under no intervention on treatment, and indicates that the gformula provides a good fit with the observational data. Additional sensitivity results for covariates are presented in Figures A2 to A5 . The g-formula estimates for AIDS onset are somewhat further from the observational data in the 1996 to 1999 baseline. This may be due to differences in confounders early in the HIV epidemic, and differences in the subset of individuals infected with HIV presenting to care. A similar process could be used to assess the calibrated CEPAC model, if the distribution of treatment initiation strategies in HIV-CAUSAL were known, by taking a weighted average of CEPAC results over the treatment strategies followed in the data.
Results
Stage
The calibration targets obtained from the g-formula under the 3 interventions of interest are reported in Table 4 . Using the g-formula, the estimated 7-y risk of mortality under immediate ART initiation was 8.0% (95% CI, 7.5 to 8. (Table 4) . Earlier treatment initiation resulted in decreased risks for both outcomes in all time periods.
The original CEPAC parameterization (using 1.0 for each of the on-treatment multipliers) resulted in 7-y mortality risk estimates that were within the 95% CIs of the g-formula estimates under all treatment strategies for 1996 to 1999, but not for the 2000 to 2002 or 2003 onwards (Table 3 , original CEPAC column). The 
Stage II: Update of the Simulation Model Parameters via Calibration to g-Formula Targets
Figure 1 displays the survival and AIDS-free survival curves from all 36 CEPAC calibration runs compared to the g-formula estimates from 2003 onwards (the CEPAC estimates are shown in grey and the observational estimates are shown in black). For the strategies of immediate initiation and initiation at CD4 \500, multiple CEPAC calibration parameter sets returned estimated survival curves that fit well with the observational estimates for both outcomes; although, survival and AIDSfree survival curves were somewhat steeper in the first 6 to 12 months of follow-up when using the g-formula (Figure 1 ). In contrast, for initiation at CD4 \350, all CEPAC calibration parameter sets underestimated both survival and AIDS-free survival as compared with the observational data ( Figure 1 ). HIV-CAUSAL estimates based on the parametric g-formula adjusted for measured time-varying confounders (CD4 count, HIV-RNA and AIDS) and baseline characteristics (calendar period and age of HIV diagnosis, risk group, gender, geographical origin, ethnicity and cohort). Figure 2 shows the 7-y mortality and combined AIDS or death risks in the 36 CEPAC calibration runs. The top left corner of each sub-figure represents the 7-y risk when the on-treatment multipliers for both OI incidence and chronic AIDS-mortality were set to 0 for a given treatment strategy. This is equivalent to a situation in which individuals on ART are not at risk for these outcomes. The bottom right corner of each sub-figure represents the scenario where both multipliers are set to 1, which would occur if the probability of OIs or chronic AIDS-related mortality was the same regardless of treatment status. In each sub-figure, the location in the heat map closest to the 7-y risk estimated from the observational data is indicated by a black box; the area of the heat map that produces estimates within the 95% CIs estimated from the observational data is enclosed in a grey box.
The g-formula mortality risk at 7 y was reproducible for immediate initiation and initiation at CD4 \500 when the multiplier for chronic AIDS-related mortality was close to zero and the multiplier for OI incidence was at or below 0.2 ( Figure 2) . For initiation at CD4 \500 cells/ml the best-fitting, on-treatment multiplier for chronic AIDS-related mortality changed to between 0.4 and 0.6. For initiation at CD4 \350, all calibration runs returned estimates greater than the upper bound of the 95% CIs from the g-formula estimates for both outcomes.
Based on the 36 calibration runs, we fine-tuned the on-treatment parameter values by applying a range of multipliers to the incidence of OIs and chronic AIDSrelated mortality in CEPAC for simulated patients on ART, and projected the overall mortality and composite outcome of AIDS or death using this grid of possible multipliers. We compared these projections to those generated by parametric g-formula estimates from HIV-CAUSAL. Subsequently, we validated the newly calibrated CEPAC projections to mortality estimates from the COHERE cohort. 37 This fine-tuning resulted in final calibrated parameter values of 0.2 for OI incidence and 0.1 for chronic AIDS-related mortality. We used these values to run CEPAC in all 3 time periods and present the risk estimates obtained from this calibrated model under the 3 treatment initiation strategies in Table 3 (calibrated CEPAC column).
The mortality risk and the combined AIDS or mortality risk estimates from the calibrated CEPAC model were very close to the corresponding observational estimates for 2003 and onwards under immediate treatment initiation and under initiation at CD4 counts above 500 cells/ ml, but over-estimated the observational estimates under initiation below 350 cells/ml (Table 3 , calibrated column). Further calibration using the approach described here could be performed to improve model performance for delayed treatment initiation strategies. Here, we omit this calibration, since our goal is to demonstrate the process of using the g-formula for calibration rather than present a full calibration of CEPAC.
Discussion
We have described a step-by-step procedure to identify counterfactual calibration targets from observational '' On-treatment multiplier for chronic AIDS-related mortality increases from 0 to 1 down the y-axis; on-treatment multiplier for opportunistic infections increases from 0 to 1 across the x-axis, following the direction of the arrows. Black boxes indicate closest matches to parametric g-formula estimates when baseline is on or after January 1, 2003; grey boxes indicate 95% CIs for parametric g-formula using 500 bootstrap samples. For the strategy ''treat at CD4 \ 350,'' no CEPAC runs resulted in risk estimates within the g-formula 95% CIs for either outcome. data for use in calibrating an individual-level simulation model. To do so, we estimated risks under several treatment strategies in an observational study (HIV-CAUSAL Collaboration) using the parametric g-formula, we identified model (CEPAC) input parameters for which empirical data did not exist, and we modified the values of these parameters to match the counterfactual outcome estimates.
The parametric g-formula allows us to estimate the outcome distributions under any treatment strategy of interest followed by at least some individuals in the data. Unlike traditional regression approaches, the parametric g-formula can provide unbiased outcome estimates even in the presence of treatment-confounder feedback; that is, even when time-varying confounders are themselves affected by prior treatment. 11, 12, 22, 38 A similar approach could be used to estimate counterfactual calibration targets under other types of interventions, such as treatment interruption, monitoring of treatment efficacy, or treatment switching, and is particularly useful when complex interventions-which depend on the evolution of time-varying markers of disease progression-are of interest. For example, the g-formula could be used to obtain calibration targets for a cardiovascular risk model under a range of statin use strategies. Finally, even when trials with appropriate interventions exist, non-adherence and loss to follow-up may make intention-to-treat estimates insufficient. In these cases, obtaining appropriate calibration targets may require adjustment for time-varying non-adherence or analysis of intermediate outcomes, and can benefit from the use of methods such as the parametric g-formula. 10, 11, 22, 39, 40 Our case study was based on the HIV-CAUSAL Collaboration, a consortium of observational cohorts that collect longitudinal data on treatments, confounders, and outcomes. The validity of this calibration procedure relies critically on the validity of the parametric g-formula estimates. The parametric g-formula requires the assumptions of no unmeasured treatment-outcome confounders and no misspecification of the parametric models for treatment, confounders, and outcomes. Although unmeasured confounding is always possible in observational studies, we adjusted our models for the main clinical indications for treatment initiation during the study period, such as CD4 count, HIV RNA, and AIDS diagnosis, as well as for other potential confounders, such as age, sex, geographic origin, and mode of transmission. We also assessed the potential for model misspecification in our parametric gformula estimates by estimating the outcome distributions under the observed distribution of treatment initiation strategies in HIV-CAUSAL, and found good agreement between the data and our model results.
In our analysis, survival and AIDS-free survival both increased substantially among the 3 baseline time periods when using the g-formula. This trend for improved survival of people living with HIV has been observed elsewhere. 42 The original CEPAC parameterization resulted in estimates that fit well with the g-formula estimates from 1996 to 1999 but not with those from most recent periods, and CEPAC does not currently model changes in parameters by calendar time. After calibration, the CEPAC model fit for the baseline period for 2003 onwards was greatly improved, especially under immediate treatment initiation and initiation at CD4 counts below 500 cells/ml.
The validity of the calibration also relies on the assumption that the population used for calibration experiences the same treatment effects and outcome risks as the target population for model inference. In our case, most HIV-CAUSAL participants live in Europe, whereas the CEPAC-US model has generally been used to estimate outcomes in the United States. Differences in access to, and cascades of, care, underlying mortality risks, or infectious disease transmission between these regions may explain some of the differences we observed for the strategy of initiating treatment at CD4 counts below 350 cells/ml in recent years. 41 Individuals who delayed treatment initiation in the post-2003 period are likely to have presented to care later in the disease process, and those presenting late may differ between US and European populations. Therefore, estimates of calibration targets based on HIV-CAUSAL for this strategy may be less appropriate to compare with US-specific CEPAC estimates.
However, a comparison of our calibrated CEPAC results with previous studies suggests that, for individuals who are retained in care and on treatment, mortality risk may not differ substantially between American and European populations. A study of a highly adherent cohort of people living with HIV in the USA found a projected mean life expectancy of 69.3 y from the time of seroconversion, 42 whereas we estimate a mean life expectancy of 67.6 y using the newly calibrated CEPAC model. The calibrated CEPAC model also matched previously published AIDS-related death rates from the COHERE collaboration within a margin of 5 deaths per 10,000 people over a 2.7-y period. Five-year survival estimates from the calibrated CEPAC model were within 2% of previously published HIV-CAUSAL estimates for the strategy of immediate treatment initiation. 20 Here, we used a simplified process for varying and assessing parameter fit: a grid search of parameter space, and a comparison with 95% CIs of the calibration targets. More sophisticated search techniques and methods of assessing goodness of fit between model outputs and calibration targets exist and could result in further improvements in the calibration. 8, [43] [44] [45] [46] [47] In addition, to focus on the process of obtaining a range of counterfactual calibration targets, we did not perform a full calibration to fit the model results for all outcomes. However, we greatly improved the fit of the CEPAC model to the strategy of immediate treatment initiation for the period of 2003 onwards, which is the strategy currently recommended for people living with HIV in the US and will therefore likely serve as a comparison strategy for future analyses. 48 In summary, the original CEPAC model performed well when compared to calibration targets estimated from data starting in the years 1996 to 1999-the time period for which the model was developed-but recalibration of CEPAC parameters was required to obtain a fit with targets estimated from 2003 onwards. This highlights the fact that populations can change over time such that periodic recalibration of individual-level simulation models may be needed to ensure that these models remain relevant over time. Similarly, recalibration of simulation models may be needed when the target of inference changes to a new population. Calibration must thus be an ongoing process to keep simulation models up-to-date and relevant for the population, or populations, of interest. However, randomized controlled trials will likely not be available for all populations or time periods of interest. The parametric g-formula can provide a solution by increasing the availability of calibration targets for these models.
